List view / Grid view
3 May 2016 | By Victoria White, Digital Content Producer
NICE has published final draft guidance recommending trametinib in combination with dabrafenib to treat some patients with melanoma...
27 April 2016 | By Mandy Parrett, Editorial Assistant
Novartis announced today that the FDA has granted three breakthrough therapy designations for Ilaris® (canakinumab) to treat rare types of Periodic Fever Syndromes, also known as Hereditary Periodic Fevers.
27 April 2016 | By Victoria White, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Entresto (sacubitril valsartan) for some people with heart failure.
21 April 2016 | By Victoria White, Digital Content Producer
Results from a Phase III study show Novartis’ Afinitor (everolimus), when used as an adjunctive therapy, significantly reduced treatment-resistant seizures...
7 April 2016 | By Victoria White
The approval includes the use of a new oral suspension formulation of Revolade designed for younger children who may not be able to swallow tablets...
21 March 2016 | By Victoria White
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ heart failure drug, Entresto (sacubitrial/valsartan).
New late-breaking data from Novartis’ head-to-head CLEAR study demonstrates that Cosentyx (secukinumab) remains superior to Stelara (ustekinumab) in achieving sustained skin clearance (PASI 90 response) at 52 weeks for adults living with moderate-to-severe psoriasis.
19 February 2016 | By Victoria White
PKC412 (midostaurin) is an investigational treatment for adults with newly-diagnosed acute myeloid leukaemia who are FLT3 mutation-positive...
18 February 2016 | By Victoria White
This Transcend Medical acquisition also expands Alcon's leadership in glaucoma and cataract treatment...
27 January 2016 | By Victoria White
Alexandra Annis states that Cosentyx's latest approval will bring exciting new treatment options to US patients dissatisfied with current therapies...
27 January 2016 | By Victoria White
NICE has published its final recommendations on whether six different drug treatments should be routinely funded by the NHS...
18 January 2016 | By Victoria White
Cosentyx (secukinumab) is a fully human monoclonal antibody that selectively neutralizes circulating interleukin-17A (IL-17A)...
11 December 2015 | By Victoria White
Sacubitril valsartan is an angiotensin receptor neprilysin inhibitor. Neprilysin inhibits the actions of peptides in dilating the blood vessels...
8 December 2015 | By Victoria White
This finding comes from from an ongoing Phase II study of CTL019 and, Novartis says, further support its potential in the treatment of paediatric patients with relapsed/refractory acute lymphoblastic leukaemia...
25 November 2015 | By Victoria White
The European Commission has granted marketing authorisation to Novartis’ Entresto (sacubitril/valsartan) for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF).
